The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Tetrabenazine
Abstract
BACKGROUND: Tetrabenazine (TBZ) depletes presynaptic dopamine in the CNS. It has been found to be beneficial in hyperkinetic movement disorders without carrying the extrapyramidal side effects that are characteristic of neuroleptics. OBJECTIVE: To summarize current knowledge on the use of TBZ and draw conclusions about its efficacy and safety. METHODS: PubMed literature searches using the term 'tetrabenazine' were carried out for the period prior to May 2009. Additional relevant studies referenced by these publications were included. CONCLUSIONS: Both short- and long-term studies have consistently yielded favorable results for the use of TBZ in the treatment of hyperkinetic movement in terms of efficacy and safety. TBZ is most effective in reducing chorea (including Huntington's disease associated chorea), tic associated with Tourette's syndrome and tardive dyskinesias. Furthermore, TBZ might also have potential for use in other hyperkinetic disorders (e.g., myoclonus and dystonia), for which future clinical trials are needed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Tetrabenazine is commonly used to treat hyperkinetic movement disorders, including TS.
“Tetrabenazine is commonly used to treat hyperkinetic movement disorders, including TS [645].”
From Reward circuitry dysfunction in psychiatric and neurodevelopmental disorders and genetic syndromes: animal models and clinical findings (2012) · cites this paper as [645]
Citations
Cites
Leckman, J. F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11526-1 · Cited by 696
Erickson, J. D., Schäfer, M., Bonner, T. I., Eiden, L. E., & Weihe, E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.5166 · Cited by 480
Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471
Long-term effects of tetrabenazine in hyperkinetic movement disorders
Jankovic, J. J., & Beach, J. (1997) · Neurology · doi:10.1212/wnl.48.2.358 · Cited by 355
Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias
Jankovic, J. J., & Orman, J. (1988) · Neurology · doi:10.1212/wnl.38.3.391 · Cited by 232
Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease
Tang, T.-S., Chen, X., Liu, J., & Борисович, Б. И. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1396-07.2007 · Cited by 207
IDIOPATHIC TORSION DYSTONIA (DYSTONIA MUSCULORUM DEFORMANS)
MARSDEN, C. D., & Harrison, M. J. (1974) · Brain · doi:10.1093/brain/97.1.793 · Cited by 207
Quinn, G. P., Shore, P. A., & Brodie, B. B. (1959) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)25665-8 · Cited by 204
Jankovic, J. J. (1986) · Archives of Neurology · doi:10.1001/archneur.1986.00520100039012 · Cited by 201
Long‐term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders
Kenney, C., Hunter, C., & Jankovic, J. J. (2006) · Movement Disorders · doi:10.1002/mds.21222 · Cited by 185
Mahant, N., McCusker, E. A., Byth, K., Graham, S., & The Huntington Study Group (2003) · Neurology · doi:10.1212/01.wnl.0000086373.32347.16 · Cited by 179
Burke, R. E., Fahn, S., Mayeux, R. P., et al. (1981) · Neurology · doi:10.1212/wnl.31.8.1022 · Cited by 170
Benzoquinolizine Derivatives: a New Class of Monamine Decreasing Drugs With Psychotropic Action
Pletscher, A., BROSSI, A., & GEY, K. F. (1962) · International review of neurobiology · doi:10.1016/s0074-7742(08)60024-0 · Cited by 168
Treatment of hyperkinetic movement disorders with tetrabenazine: A double‐blind crossover study
Jankovic, J. J. (1982) · Annals of Neurology · doi:10.1002/ana.410110108 · Cited by 165
Pasricha, P. J., Pehlivanov, N., Sugumar, A., & Jankovic, J. (2006) · Nature Clinical Practice Gastroenterology &Hepatology · doi:10.1038/ncpgasthep0442 · Cited by 163
The trial use of clozapine for abnormal involuntary movement disorders
Caine, E. D., Polinsky, R. J., Kartzinel, R., & Ebert, M. H. (1979) · American Journal of Psychiatry · doi:10.1176/ajp.136.3.317 · Cited by 161
Tetrabenazine in the treatment of hyperkinetic movement disorders
Kenney, C., & Jankovic, J. J. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.1.7 · Cited by 158
The current clinical management of Huntington's disease
Phillips, W., Shannon, K. M., & Barker, R. A. (2008) · Movement Disorders · doi:10.1002/mds.21971 · Cited by 158
Pharmacological Management of Huntingtons Disease: An Evidence- Based Review
Bonelli, R. M., & Wenning, G. K. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206777698693 · Cited by 156
The treatment of severe dystonia in children and adults.
MARSDEN, C. D., Marion, M.-H., & Quinn, N. P. (1984) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.47.11.1166 · Cited by 151
Tetrabenazine Treatment for Tardive Dyskinesia: Assessment by Randomized Videotape Protocol
Ondo, W. G., Hanna, P. A., & Jankovic, J. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.8.1279 · Cited by 149
Treatment of Tardive Dyskinesia
Kazamatsuri, H. (1972) · Archives of General Psychiatry · doi:10.1001/archpsyc.1972.01750250081011 · Cited by 140
Pathophysiology of Huntingtonʼs disease: from huntingtin functions to potential treatments
Roze, E. F., Saudou, F., & Caboche, J. (2008) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328304b692 · Cited by 131
Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome
Jankovic, J. J., Glaze, D. G., & Frost, J. D. (1984) · Neurology · doi:10.1212/wnl.34.5.688 · Cited by 130
Long-Term Treatment of Tardive Dyskinesia with Haloperidol and Tetrabenazine
Kazamatsuri, H., Chien, C., & Cole, J. O. (1973) · American Journal of Psychiatry · doi:10.1176/ajp.130.4.479 · Cited by 125
Pettibone, D. J., Totaro, J. A., & Pflueger, A. B. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90562-4 · Cited by 118
Management of status dystonicus: Our experience and review of the literature
Mariotti, P., Fasano, A. A., Contarino, M. F., et al. (2007) · Movement Disorders · doi:10.1002/mds.21471 · Cited by 116
Self-citationClozapine versus placebo in Huntington's disease: a double blind randomised comparative study
van Vugt, J. P. P., Siesling, S., Vergeer, M., van der Velde, E. A., & Roos, R. A. C. (1997) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.63.1.35 · Cited by 115
Motor, Behavioral and Pharmacologic Findings in Tourette's Syndrome
Jankovic, J. J., & Rohaidy, H. (1987) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100038087 · Cited by 111
Tetrabenazine Treatment in Movement Disorders
Paleacu, D., Giladi, N., Moore, O., et al. (2004) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000136892.24629.96 · Cited by 98
Stacy, M. A., & Jankovic, J. J. (1992) · Movement Disorders · doi:10.1002/mds.870070110 · Cited by 95
Brusa, L., Orlacchio, A., Moschella, V., Iani, C., Bernardi, G., & Mercuri, N. B. (2008) · Movement Disorders · doi:10.1002/mds.22376 · Cited by 91
Tetrabenazine Treatment for Huntington's Disease-Associated Chorea
Ondo, W. G., Tintner, R., Thomas, M., & Jankovic, J. J. (2002) · Clinical Neuropharmacology · doi:10.1097/00002826-200211000-00003 · Cited by 89
A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia.
Quinn, N. P., & MARSDEN, C. D. (1984) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.47.8.844 · Cited by 84
GPi‐DBS in Huntington's disease: Results on motor function and cognition in a 72‐year‐old case
Fasano, A. A., Mazzone, P. A. M., Piano, C., et al. (2008) · Movement Disorders · doi:10.1002/mds.22116 · Cited by 80
Self-citationTardive stereotypy and other movement disorders in tardive dyskinesias
Stacy, M. A., Cardoso, F., & Jankovic, J. J. (1993) · Neurology · doi:10.1212/wnl.43.5.937 · Cited by 79
Presynaptic Catecholamine Antagonists as Treatment for Tourette Syndrome
Sweet, R. D. (1974) · Archives of General Psychiatry · doi:10.1001/archpsyc.1974.01760180095012 · Cited by 77
Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.
Reches, A., Burke, R. E., Kuhn, C. M., Hassan, M. N., Jackson, V., & Fahn, S. (1983) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33621-9 · Cited by 75
Nithsdale Schizophrenia Surveys 23: movement disorders
Halliday, J., Farrington, S. M., Macdonald, S., MacEwan, T., Sharkey, V., & McCreadie, R. G. (2002) · The British Journal of Psychiatry · doi:10.1192/bjp.181.5.422 · Cited by 75
Tetrabenazine and movement disorders
Asher, S. W., & Aminoff, M. J. (1981) · Neurology · doi:10.1212/wnl.31.8.1051 · Cited by 72
A DOUBLE-BLIND TRIAL OF TETRABENAZINE, THIOPROPAZATE, AND PLACEBO IN PATIENTS WITH CHOREA
McLellan, D. L. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92338-1 · Cited by 72
Tetrabenazine induces acute dystonic reactions
Burke, R. E., Reches, A., Traub, M., et al. (1985) · Annals of Neurology · doi:10.1002/ana.410170217 · Cited by 68
Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile
González, A. M., Walther, D. M., Pazos, Á., & Uhl, G. R. (1994) · Molecular Brain Research · doi:10.1016/0169-328x(94)90050-7 · Cited by 67
A Study of Chorea After Tetrabenazine Withdrawal in Patients With Huntington Disease
Frank, S., Ondo, W. G., Fahn, S., et al. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e3180ca77ea · Cited by 67
Tetrabenazine has properties of a dopamine receptor antagonist
Login, I. S., Cronin, M. J., & MacLeod, R. M. (1982) · Annals of Neurology · doi:10.1002/ana.410120308 · Cited by 66
A Double Blind Trial of Lithium Carbonate and Haloperidol in Huntington's Chorea
Leonard, D., Kidson, M. A., Brown, J. G. E., et al. (1975) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048677509159834 · Cited by 62
Short‐term effects of tetrabenazine on chorea associated with Huntington's disease
Kenney, C., Hunter, C., Davidson, A. L., et al. (2006) · Movement Disorders · doi:10.1002/mds.21161 · Cited by 60
Gilles de la Tourette Syndrome
McHenry, L. C. (1978) · JAMA · doi:10.1001/jama.1978.03290040072036 · Cited by 60
Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea
Deroover, J., Baro, F., Bourguignon, R. P., & Smets, P. (1984) · Current Medical Research and Opinion · doi:10.1185/03007998409109601 · Cited by 60
Hoehn, M. M. M., & Cherington, M. (1977) · Neurology · doi:10.1212/wnl.27.10.942 · Cited by 60
Is History of Depression a Contraindication to Treatment With Tetrabenazine?
Kenney, C., Hunter, C., Mejia, N. I., et al. (2006) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000228369.25593.35 · Cited by 56
The Long-term Effect of Tetrabenazine in the Management of Huntington Disease
Fasano, A. A., Cadeddu, F., Guidubaldi, A., et al. (2008) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318166da60 · Cited by 53
Self-citationScherman, D., Boschi, G., Rips, R., et al. (1986) · Brain Research · doi:10.1016/0006-8993(86)91120-0 · Cited by 50
Mehvar, R., Jamali, F., Watson, M., & Skelton, D. R. (1987) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06690-5 · Cited by 48
Tiapride in the treatment of Huntington's chorea
Roos, R. A. C., Buruma, O. J. S., Bruyn, G. W., et al. (1982) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1982.tb03060.x · Cited by 47
Tetrabenazine in the treatment of severe pediatric chorea
Chatterjee, A. K., & Frucht, S. J. (2003) · Movement Disorders · doi:10.1002/mds.10427 · Cited by 42
Thibaut, F., Faucheux, B. A., Marquez, J., et al. (1995) · Brain Research · doi:10.1016/0006-8993(95)00674-f · Cited by 41
Tetrabenazine as a cause of neuroleptic malignant syndrome
Ossemann, M., Sindic, C., & Laterre, C. (1996) · Movement Disorders · doi:10.1002/mds.870110118 · Cited by 41
A case of tetrabenazine‐induced neuroleptic malignant syndrome after prolonged treatment
Petzinger, G. M., & Bressman, S. (1997) · Movement Disorders · doi:10.1002/mds.870120219 · Cited by 39
Roberts, M. S., McLean, S., Millingen, K. S., et al. (1986) · European Journal of Clinical Pharmacology · doi:10.1007/bf00615962 · Cited by 37
Mateo, D., Muñoz-Blanco, J. L., & Giménez-Roldán, S. (1992) · Clinical Neuropharmacology · doi:10.1097/00002826-199202000-00009 · Cited by 34
THE EFFECT OF TETRABENAZINE IN SOME HYPERKINETIC SYNDROMES
Pakkenberg, H. (1968) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1968.tb05581.x · Cited by 34
Concentration–Effect Relationships of Tetrabenazine and Dihydrotetrabenazine in the Rat
Mehvar, R., & Jamali, F. (1987) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600760610 · Cited by 31
Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease
PEARSON, S., & Reynolds, G. P. (1988) · Neuropharmacology · doi:10.1016/0028-3908(88)90080-9 · Cited by 28
TETRABENAZINE FOR INVOLUNTARY MOVEMENT DISORDERS
Kingston, D. (1979) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1979.tb119426.x · Cited by 24
TETRABENAZINE IN THE TREATMENT OF HUNTINGTON'S CHOREA
Huang, C. Y., McLeod, J. G., HOLLAND, R. T., et al. (1962) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1976.tb140870.x · Cited by 23
Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia
Stevens, E., Roman, A., Houa, M., et al. (1998) · Intensive Care Medicine · doi:10.1007/s001340050583 · Cited by 20
Olanzapine-Induced Tardive Dystonia Successfully Treated by Tetrabenazine
Rauchverger, B., Isakov, V., & Jabarin, M. (2007) · Journal of Neuropsychiatry · doi:10.1176/jnp.2007.19.4.484a · Cited by 19
Roberts, M. S., Watson, H. M., McLean, S., et al. (1981) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/s0378-4347(00)84218-8 · Cited by 17
Treatment of Tardive Dyskinesia: Preliminary Report on Use of Tetrabenazine
Watson, M. W. B., Skelton, D. R., & Jamali, F. (1988) · The Canadian Journal of Psychiatry · doi:10.1177/070674378803300104 · Cited by 16
Storey, E., & Lloyd, J. (1997) · Movement Disorders · doi:10.1002/mds.870120533 · Cited by 15
Zaidi, S. H. H., & Faruqui, R. A. (2008) · Brain Injury · doi:10.1080/02699050701822493 · Cited by 13
THE MODE OF ACTION OF TETRABENAZINE ON PERIPHERAL NORADRENERGIC NERVES
Tomlinson, D. R. (1977) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1977.tb08425.x · Cited by 13
Satou, T., Anderson, A. J., Itoh, T., et al. (2001) · Experimental and Toxicologic Pathology · doi:10.1078/0940-2993-00195 · Cited by 12
Self‐poisoning with Tetrabenazine
Kidd, D. W., & McLellan, D. L. (1972) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1972.tb04414.x · Cited by 12
Evaluation and Treatment of Dystonia
Scott, B. L. (2000) · Southern Medical Journal · doi:10.1097/00007611-200008000-00001 · Cited by 5
Louis (1999) · doi:10.1002/1531-8257(199905)14:3
Flagged first, then by citations
Research works printed but not linked: 6
- Lende N, 1960, Dis Nerv Syst, 21, 118
- Jankovic J, 1983, Adv Neurol, 37, 277
- Gimenez-Roldan S, 1989, Neurologia, 4, 282
- Mestre T, 2009, Cochrane Database Syst Rev, CD006456
- Kenney C, 2007, J Pediatric Neurol, 5, 9
- Jankovic J, 2004, Adv Neurol, 94, 275
Cited by
Sorted by citations
Dichter, G. S., Damiano, C. A., & Allen, J. A. (2012) · Journal of Neurodevelopmental Disorders · doi:10.1186/1866-1955-4-19 · Cited by 299
Metadata
- Authors
- Fasano, A., & Bentivoglio, A. R.
- Affiliations
- Università Cattolica del Sacro Cuore (IT)
- Venue
- Expert Opinion on Pharmacotherapy
- Publisher
- Informa UK Limited
- Published
- 2009-11-25
- Volume
- 10
- Issue
- 17
- Pages
- 2883-2896
- ISSN
- 1465-6566 (ISSN-L)
- 1744-7666
- OpenAlex
- W4239925697
- Cited by
- 51
- References
- 77
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 4 · 2022: 4 · 2021: 3 · 2018: 2 · 2017: 2 · 2016: 3 · 2015: 4 · 2014: 4 · 2013: 4 · 2012: 7
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Pharmacotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Health Sciences › Medicine › Clinical Neurology › Neurological and metabolic disorders
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- tetrabenazine, dopamine depletion, hyperkinetic movement disorders, chorea, Huntington's disease, Tourette syndrome, tardive dyskinesia, myoclonus, dystonia, drug efficacy, drug safety, extrapyramidal symptoms
- MeSH terms
- Animals, Drug Interactions, Humans, Nervous System Diseases, Tetrabenazine, Randomized Controlled Trials as Topic, Adrenergic Uptake Inhibitors, Models, Animal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review